Intellia Therapeutics (NASDAQ:NTLA) PT Lowered to $88.00

Intellia Therapeutics (NASDAQ:NTLA) had its price objective dropped by investment analysts at Chardan Capital from $94.00 to $88.00 in a report released on Thursday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. Chardan Capital’s price target indicates a potential upside of 451.72% from the stock’s previous close.

A number of other equities research analysts have also issued reports on the stock. Royal Bank of Canada reaffirmed an “outperform” rating and set a $54.00 target price on shares of Intellia Therapeutics in a report on Thursday, September 19th. JPMorgan Chase & Co. dropped their target price on Intellia Therapeutics from $61.00 to $55.00 and set an “overweight” rating for the company in a report on Monday, August 12th. StockNews.com raised Intellia Therapeutics to a “sell” rating in a research note on Thursday, June 27th. Canaccord Genuity Group reissued a “buy” rating and set a $73.00 price target on shares of Intellia Therapeutics in a research report on Thursday, June 27th. Finally, Stifel Nicolaus cut their price objective on shares of Intellia Therapeutics from $80.00 to $64.00 and set a “buy” rating for the company in a research report on Wednesday, September 11th. One analyst has rated the stock with a sell rating, five have issued a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $59.13.

Intellia Therapeutics Price Performance

NTLA opened at $15.95 on Thursday. The stock has a market cap of $1.62 billion, a P/E ratio of -2.91 and a beta of 1.76. The firm has a fifty day moving average price of $20.71 and a 200 day moving average price of $22.75. Intellia Therapeutics has a 1 year low of $15.35 and a 1 year high of $34.87.

Intellia Therapeutics (NASDAQ:NTLA) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($1.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.29). The business had revenue of $7.00 million for the quarter, compared to analyst estimates of $19.68 million. The business’s revenue for the quarter was down 48.5% on a year-over-year basis. During the same period in the prior year, the business posted ($1.40) EPS. Equities analysts expect that Intellia Therapeutics will post -5.22 EPS for the current year.

Insiders Place Their Bets

In related news, CAO Michael P. Dube sold 2,012 shares of the business’s stock in a transaction on Wednesday, October 2nd. The stock was sold at an average price of $19.01, for a total value of $38,248.12. Following the sale, the chief accounting officer now owns 47,012 shares in the company, valued at approximately $893,698.12. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 3.20% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in NTLA. Dimensional Fund Advisors LP lifted its holdings in Intellia Therapeutics by 8.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,324,561 shares of the company’s stock worth $29,648,000 after buying an additional 98,865 shares in the last quarter. Thrivent Financial for Lutherans acquired a new stake in shares of Intellia Therapeutics in the second quarter valued at $679,000. American Century Companies Inc. boosted its holdings in Intellia Therapeutics by 23.8% in the second quarter. American Century Companies Inc. now owns 330,514 shares of the company’s stock valued at $7,397,000 after purchasing an additional 63,550 shares during the period. Vanguard Group Inc. grew its stake in Intellia Therapeutics by 1.9% during the 4th quarter. Vanguard Group Inc. now owns 8,347,449 shares of the company’s stock worth $254,514,000 after purchasing an additional 155,579 shares in the last quarter. Finally, Comerica Bank increased its holdings in Intellia Therapeutics by 853.6% during the 1st quarter. Comerica Bank now owns 37,105 shares of the company’s stock worth $1,021,000 after purchasing an additional 33,214 shares during the period. Institutional investors and hedge funds own 88.77% of the company’s stock.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.